BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study
Clinical Trial Update: BriaCell Therapeutics is conducting a pivotal Phase 3 study of its Bria-IMT™ combination therapy with an immune checkpoint inhibitor for metastatic breast cancer, with patient enrollment expected to complete by mid-2025 and interim data analysis planned after 144 deaths occur.
Safety and Efficacy: No serious adverse events related to Bria-IMT™ have been reported, and positive results from the study could lead to full approval and marketing authorization for the treatment in patients who have not responded to existing therapies.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on BCTXW
No data
About the author
BRIACELL THERAPEUTICS COMPLETES $30 MILLION PUBLIC OFFERING
Company Announcement: BRIACELL THERAPEUTICS has announced the closing of a public offering.
Financial Details: The offering raised a total of US$30 million.
BriaCell Chosen to Showcase Phase 2 and 3 Clinical Findings at SABCS® 2025
BriaCell's Presentations at SABCS: BriaCell Therapeutics will present three clinical and one preclinical posters at the 2025 San Antonio Breast Cancer Symposium, showcasing key biomarker data and survival results from their studies on Bria-IMT™ and other therapies for metastatic breast cancer.
Significant Data Sharing: The presentations include late-breaking clinical posters that aim to provide substantial data to leading breast cancer experts, with the goal of improving clinical outcomes for cancer patients.
Poster Presentation Details: Key presentations include topics on the impact of prior therapy and biomarkers in the Bria-ABC Phase 3 Trial, survival results from the Phase II Bria-IMT vaccine, and cytokine signatures as biomarkers of clinical benefit in breast cancer vaccination.
Company Overview: BriaCell is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance cancer care, with more information available on their website.
